AEON Biopharma Submits IND for Comparative Pharmacodynamic Study of ABP-450
AEON Biopharma Inc AEON
$0.17
▼ -4.84%
($-0.01)
🔥 High Short Interest
📅 Earnings This Week
Open
$0.19
Prev Close
$0.18
Day Range
$0.17 – $0.19
52W Range
$0.13 – $1.45
Market Cap
$10.74M
Beta
0.67
EPS (TTM)
$-3.58
📋 Company Profile
| Industry | N/A |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2021-10-08 |
| Shares Out. | 37,155,500 |
| Website | aeonbiopharma.com/ ↗ |
| Phone | 19492844555.0 |
| Employees | 8 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$1.2M |
| Free Cash Flow | -$13.6M |
| Total Assets | $5.9M |
| Total Liabilities | $21.3M |
| Equity | -$15.4M |
About AEON Biopharma Inc
AEON Biopharma Inc is a biopharmaceutical company focused on the development of ABP-450 (prabotulinumtoxinA), a biosimilar to Botox (onabotulinumtoxinA), for therapeutic indications. The company is advancing ABP-450 through the biosimilar regulatory pathway and holds development and commercialization rights across multiple international markets.
AEON Biopharma Inc is a publicly traded company under the ticker symbol AEON on the NASDAQ NMS - GLOBAL MARKET, operating in the N/A industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
10 analysts (2026-11-01)